CD274 and breast carcinoma: Furthermore, the use of T-DXd in combination with other therapies is also being explored, such as in combination with pertuzumab in metastatic breast cancer (NCT04784715), durvalumab (anti-PD-L1 and NCT04538742), tucatinib (TKI targeting HER2, NCT04538742, and NCT04539938) in metastatic HER2+ breast cancer, and even in HER2-low breast cancer in combination with several distinct drugs (NCT04556773) [104].